PLASMA Trial: Phospholipase Levels And Serological Markers of Atherosclerosis: a dose-response clinical pharmacology study of A-002 [varespladib] in subjects with stable coronary artery disease

Trial Profile

PLASMA Trial: Phospholipase Levels And Serological Markers of Atherosclerosis: a dose-response clinical pharmacology study of A-002 [varespladib] in subjects with stable coronary artery disease

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2009

At a glance

  • Drugs Varespladib (Primary)
  • Indications Atherosclerosis; Coronary disorders
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms PLASMA
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 21 Feb 2009 Results published in The Lancet.
    • 01 Apr 2008 Results were reported at the 57th Annual Scientific Session of the American College of Cardiology.
    • 07 Feb 2008 Results will be presented at ACC 2008 on 31 March as a late breaker abstract.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top